Lithium carbonate as a mood stabilizer ，is the first -line treatment for bipolar disorder （BD）. Due to the narrow treatment range and large individual respons e differences ，physiological and pathological states and drug interactions can affect its therapeutic effect ；as therapeutic drug monitoring （TDM），population pharmacokinetics （PPK）and pharmacogenomics play an increasingly important role in the individualized use of lithium carbonate ，how to optimize the individualized use of lithium carbonate more effectively has attracted much attention . This paper reviewed the latest research progress of TDM ，PPK and pharmacogenomics in the individualized treatment of lithium carbonate in recent years . Due to the influence of patients ’ pathophysiological status ，the target blood concentration range of lithium among different populations was slightly different . To ensure its efficacy and safety ，routine TDM was required . PPK studies conducted in different populations showed that the relevant predictors used to optimize lithium treatment included body mass ，lean body mass ，age and renal function ，etc. Pharmacogenomics research showed that the single nucleotide polymorphisms of FKBP5，ACP1，ADCY2 and other genes were related to the difference of patients ’treatment response . Therefore，on the basis of routine TDM for lithium carbonate ，the comprehensive evaluation combined with PPK and pharmacogenomics is of great significance for the individual treatment of lithium carbonate .